Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

By afschroeder • September 22, 2025

Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576-4. Epub ahead of print. PMID: 40976249.

Tags: Dermatology, Publications

Reply to Botto et al’s “Applicant interview metrics and preference signaling in dermatology: A serial cross-sectional study”

Fleshner L, Chan R, Klufas T, Grant-Kels JM, Zhou AE. Reply to Botto et al's "Applicant interview metrics and preference signaling in dermatology: A serial[...]

Identification of a spatially organized TREM2-associated permissive macrophage niche in human pulmonary tuberculosis alveolar pneumonia

Teles RMB, Benabdessalem C, Perrie J, Wei C, West J, de Andrade Silva BJ, Andrade PR, Mansky LA, Divaka P, Fischbacher L, Lam K, Ma[...]

The State of Mohs Micrographic Surgery in 2025-2026: Current Challenges, Pressures, and the Path Forward

Zhou AE, Gronbeck C, Kim JJ, Yu S, Feng H, Klufas DM. The State of Mohs Micrographic Surgery in 2025-2026: Current Challenges, Pressures, and the[...]